Exactech Announces Successful First Surgeries with Truliant® Knee System

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, is pleased to announce that the first surgeries using the new Truliant® Knee System were performed yesterday. Truliant, which recently received 510(k) clearance from the U.S. Food and Drug Administration, offers a comprehensive portfolio of implants and instrumentation designed to help surgeons address the remaining clinical challenges of total knee replacement.

Craig Morrison, MD, of the Southern Joint Replacement Institute in Nashville, Tenn., and Michael Dayton, MD, from the University of Colorado in Denver, Colo. were the first surgeons to use the new knee system. According to Dr. Dayton, “The Truliant system has the advantage of being very user-friendly from the standpoint of ergonomic instrumentation. It should allow me to more accurately size, balance and efficiently perform the surgeries.”

Advertisement

“The Truliant system is intuitive,” Dr. Morrison said. “What I saw today is that you put the instrument in a surgeon’s hand, and they know what to do with it right away. I think the competitive advantage of this system is going to be how easily Truliant accommodates a surgeon’s preferred workflow.”

Designed with the ultimate surgical experience in mind, the Truliant Knee System is a high-performance, comprehensive platform that addresses the clinical challenges in primary and revision total knee replacement. Leveraging Exactech’s core principles, Truliant applies advanced design philosophies and surgical technologies to help surgeons deliver clinical outcomes reproducibly case after case.

According to Exactech’s Vice President of Knee Marketing Joseph Pizzurro, “With the number of knee arthroplasty surgeries on the rise, there is a market and clinical need for a system that offers enhanced efficiency and overall reproducibility. Based on input from a wide array of surgeons, Exactech’s design team of engineers and surgeon consultants converged to develop a modern, fully comprehensive knee system that offers a broad range of implants, intuitive instrumentation and computer-assisted technology to accommodate a variety of surgical approaches and philosophies. We are thrilled to introduce Truliant to the marketplace.”

Surgeons cite Exactech’s collaborative culture as a key to the new knee system’s intuitive design. “The people at Exactech are always leaning forward and engaging the surgeons,” said Ronald Hillock, MD, an orthopaedic surgeon in Las Vegas, Nev. “They have been very receptive to feedback, and I’ve always been impressed with the depth of their interest, from the top down. Everybody is in tune with designing a product that will give the best outcomes. It is engrained in their culture and it definitely comes through the products. Truliant is a prime example.”

Truliant is in pilot launch with a group of U.S. surgeons. Full market availability is expected in the United States during 2018.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

A current investment profile on Exactech (Nasdaq: EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.